![A detailed ‘atlas’ of neuroblastoma tumors points to a new target for immunotherapy – Prinses Máxima Centrum voor kinderoncologie](https://oncodaily.com/pub/uploads/2024/01/73019686489.png)
A detailed ‘atlas’ of neuroblastoma tumors points to a new target for immunotherapy – Prinses Máxima Centrum voor kinderoncologie
Quoting Prinses Máxima Centrum voor kinderoncologie on LinkedIn:
“A detailed ‘atlas’ of neuroblastoma tumors points to a new target for immunotherapy. Scientists from the Molenaar group mapped this childhood tumor at the level of individual cancer and immune cells. In doing so, they discovered a brake on the immune system that can be blocked with existing immunotherapy. The results in the lab are promising; preparations for a clinical trial are underway.
Prof. Dr. Jan Molenaar: ‘It’s fantastic that we can immediately translate the results of very basic research into the biology of neuroblastoma into the clinic – I have never experienced that translation happening so quickly before. I look forward to starting the clinical trial to ultimately see whether children with neuroblastoma will benefit from this new combination of immunotherapies.”
Source: Prinses Máxima Centrum voor kinderoncologie/LinkedIn
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023